Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa. However, details of the emicizumab–antigen interactions have not been reported so far. In this study, we first showe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitazawa, Takehisa, Esaki, Keiko, Tachibana, Tatsuhiko, Ishii, Shinya, Soeda, Tetsuhiro, Muto, Atsushi, Kawabe, Yoshiki, Igawa, Tomoyuki, Tsunoda, Hiroyuki, Nogami, Keiji, Shima, Midori, Hattori, Kunihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Schattauer GmbH 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292136/
https://www.ncbi.nlm.nih.gov/pubmed/28451690
http://dx.doi.org/10.1160/TH17-01-0030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292136/
https://www.ncbi.nlm.nih.gov/pubmed/28451690
http://dx.doi.org/10.1160/TH17-01-0030

Ejemplares similares